Paolo Palmisciano1, Ali S Haider2, Kishore Balasubramanian3, Randy S D'Amico4, Alla Gabriella Wernicke5,6. 1. Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 2. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 3. Texas A&M University College of Medicine, Houston, TX, USA. 4. Department of Neurological Surgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA. 5. Department of Radiation Oncology, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA. gwernicke@northwell.edu. 6. Department of Radiation Medicine, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra, 130 East 77th Street, New York, NY, 10075, USA. gwernicke@northwell.edu.
Abstract
PURPOSE: Cesium-131 radioactive isotope has favored the resurgence of intracavitary brachytherapy in neuro-oncology, minimizing radiation-induced complications and maximizing logistical and clinical outcomes. We reviewed the literature on cesium-131 brachytherapy for brain tumors. METHODS: PubMed, Web-of-Science, Scopus, Clinicaltrial.gov, and Cochrane were searched following the PRISMA extension for scoping reviews to include published studies and ongoing trials reporting cesium-131 brachytherapy for brain tumors. RESULTS: We included 27 published studies comprising 279 patients with 293 lesions, and 3 ongoing trials. Most patients had brain metastases (63.1%), followed by high-grade gliomas (23.3%), of WHO Grade III (15.2%) and Grade IV (84.8%), and meningiomas (13.6%), mostly of WHO Grade II (62.8%) and Grade III (27.9%). Most brain metastases were newly diagnosed (72.3%), while most gliomas and meningiomas were recurrent (95.4% and 88.4%). Patients underwent gross-total (91.1%) or subtotal (8.9%) resection, with median postoperative cavity size of 3.5 cm (range 1-5.8 cm). A median of 20, 28, and 16 seeds were implanted in gliomas, meningiomas, and brain metastases, with median seed activity of 3.8 mCi (range 2.4-5 mCi). Median follow-up was 16.2 months (range 0.6-72 months). 1-year freedom from progression rates were local 94% (range 57-100%), regional 85.1% (range 55.6-93.8%), and distant 53.5% (range 26.3-67.4%). Post-treatment radiation necrosis, seizure, and surgical wound infection occurred in 3.4%, 4.7%, and 4.3% patients. CONCLUSION: Initial data suggest that cesium-131 brachytherapy is safe and effective in primary or metastatic malignant brain tumors. Ongoing trials are evaluating long-term locoregional tumor control and future studies should analyze its role in multimodal systemic tumor management.
PURPOSE: Cesium-131 radioactive isotope has favored the resurgence of intracavitary brachytherapy in neuro-oncology, minimizing radiation-induced complications and maximizing logistical and clinical outcomes. We reviewed the literature on cesium-131 brachytherapy for brain tumors. METHODS: PubMed, Web-of-Science, Scopus, Clinicaltrial.gov, and Cochrane were searched following the PRISMA extension for scoping reviews to include published studies and ongoing trials reporting cesium-131 brachytherapy for brain tumors. RESULTS: We included 27 published studies comprising 279 patients with 293 lesions, and 3 ongoing trials. Most patients had brain metastases (63.1%), followed by high-grade gliomas (23.3%), of WHO Grade III (15.2%) and Grade IV (84.8%), and meningiomas (13.6%), mostly of WHO Grade II (62.8%) and Grade III (27.9%). Most brain metastases were newly diagnosed (72.3%), while most gliomas and meningiomas were recurrent (95.4% and 88.4%). Patients underwent gross-total (91.1%) or subtotal (8.9%) resection, with median postoperative cavity size of 3.5 cm (range 1-5.8 cm). A median of 20, 28, and 16 seeds were implanted in gliomas, meningiomas, and brain metastases, with median seed activity of 3.8 mCi (range 2.4-5 mCi). Median follow-up was 16.2 months (range 0.6-72 months). 1-year freedom from progression rates were local 94% (range 57-100%), regional 85.1% (range 55.6-93.8%), and distant 53.5% (range 26.3-67.4%). Post-treatment radiation necrosis, seizure, and surgical wound infection occurred in 3.4%, 4.7%, and 4.3% patients. CONCLUSION: Initial data suggest that cesium-131 brachytherapy is safe and effective in primary or metastatic malignant brain tumors. Ongoing trials are evaluating long-term locoregional tumor control and future studies should analyze its role in multimodal systemic tumor management.
Authors: Kari Tanderup; Cynthia Ménard; Csaba Polgar; Jacob Christian Lindegaard; Christian Kirisits; Richard Pötter Journal: Adv Drug Deliv Rev Date: 2016-09-13 Impact factor: 15.470
Authors: A Gabriella Wernicke; Menachem Z Yondorf; Luke Peng; Samuel Trichter; Lucy Nedialkova; Albert Sabbas; Fridon Kulidzhanov; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; Paul Christos; Ilhami Kovanlikaya; Susan Pannullo; John A Boockvar; Philip E Stieg; Theodore H Schwartz Journal: J Neurosurg Date: 2014-05-02 Impact factor: 5.115
Authors: N J Laperriere; P M Leung; S McKenzie; M Milosevic; S Wong; J Glen; M Pintilie; M Bernstein Journal: Int J Radiat Oncol Biol Phys Date: 1998-07-15 Impact factor: 7.038
Authors: Robert G Selker; William R Shapiro; Peter Burger; Margaret S Blackwood; Vincent C Arena; John C Gilder; Mark G Malkin; John J Mealey; John H Neal; Jeffrey Olson; James T Robertson; Gene H Barnett; Stephen Bloomfield; Robert Albright; Fred H Hochberg; Emile Hiesiger; Sylvan Green Journal: Neurosurgery Date: 2002-08 Impact factor: 4.654